Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQuartix Tech Regulatory News (QTX)

Share Price Information for Quartix Tech (QTX)

Share Price is delayed by 15 minutes
Get Live Data
262.50    -2.50 (-0.94%)
Bid:
260.00
Ask:
265.00
Spread: 5.00 (1.923%)
Market Cap: £127.20m
QTX Live PriceLast checked at - London Stock Exchange

Intraday Quartix Tech Share Chart

Konetik update

11 Dec 2023 07:00

RNS Number : 2500W
Quartix Technologies PLC
11 December 2023
 

Quartix Technologies plc

("Quartix", "the Group" or "the Company")

Konetik update.

The Company announced the acquisition of Konetik on 15 September 2023. As noted in the trading update of 6 October 2023, a detailed review of the acquisition of Konetik Deutschland GmbH ("Konetik") and the potential for the Company's Evolve product line, a tool that assists fleet managers with planning their migration to electric vehicles, has now been completed. Following his return to the Company and appointment to the Board as Chairman on 26 September 2023, Andy Walters, major shareholder and founder of the Company, led this review.

Launched in 2022, the Evolve product has been sold as an upgrade to a small number of existing customers, principally in the UK public sector, and revenue generated to date has been very limited. Whilst users are pleased with reports provided by Evolve, repeat usage by most has been very low and renewal rates for early adopters has been disappointing. Following the review, the board considers that the ability to increase the customer base and scale the business in the next two years will be substantially more challenging than had been envisaged at the time of making the acquisition. This is due to:

1. demand for Evolve, particularly in the private sector, has been adversely impacted by delays to EV transition deadlines with the UK government's decision to postpone the ban on the sale of petrol and diesel vehicles to 2035.

2. the ability to generate substantial increases in the volume of license sales is now expected to require much higher investment in the software infrastructure due to limitations in the scalability of the current product

3. the customer acquisition cost and implementation support are now expected to be much higher than previously anticipated

4. the customer lifetime is now expected to be significantly shorter than previously anticipated

 

In addition, the Board considers that the Evolve product is not an effective tool for the acquisition of new vehicle tracking customers. Finally, the anticipated resource requirements for the development, sale, support and maintenance of Evolve means that such investment is not anticipated to achieve an appropriate return.

Following this review the Board is committed to reducing the impact of this acquisition on the operating performance of the Company as soon as possible. However, a further consequence of the conclusion of the review is, regrettably, that a substantial, one time, non-cash impairment in the goodwill arising from the Konetik acquisition (£2.5 million) will need to be made in the Company's 2023 financial statements. 

Quartix generates strong recurring revenues and operational cashflows from its subscription base and the Company will refocus its efforts on its primary strategic objective of delivering profitable growth in this core business.

Andy Walters, Executive Chairman, commented:

"Quartix provides subscription-based telematics services to more than 26,000 customers, for more than a quarter of a million commercial vehicles. Over the past 5 years Quartix has added new territories and developed additional channels to market which offer exciting growth potential for the future.

Since my return to the Company at the end of September I have been very grateful for the support of the executive management team in conducting this review and am delighted that I have their full commitment to returning the Company's focus to its core business."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as retained as part of UK law by virtue of the European Union (Withdrawal) Act 2018 as amended.

 

For further information, please contact:

Quartix (www.quartix.net)

Andy Walters, Executive Chairman

Emily Rees, Chief Financial Officer

01686 806 663

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Matt Goode / Seamus Fricker (Corporate Finance)

Tim Redfern / Sunila de Silva (Corporate Broking)

020 7220 0500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDFFFIIFSLTIIV
Date   Source Headline
2nd Jun 202612:17 pmRNSDirector/PDMR Shareholding
22nd Apr 20265:20 pmRNSResult of AGM
22nd Apr 20267:00 amRNSTrading Statement
8th Apr 202612:16 pmRNSDirector/PDMR Dealing, TVR & Investor Webinar
25th Mar 20267:00 amRNSFinal Results
20th Mar 20264:18 pmRNSNotice of Results
23rd Feb 20267:00 amRNSNotice of Results
11th Feb 20267:00 amRNSFRC Review, Accounting Policy & Notice of Results
8th Jan 20267:00 amRNSTrading Update
15th Dec 20255:47 pmRNSDirector/PDMR Shareholding
18th Nov 20252:15 pmRNSHolding(s) in Company
27th Oct 202512:49 pmRNSDirector/PDMR Shareholding
6th Oct 20255:37 pmRNSGrant of Options
6th Oct 20257:01 amRNS-RMelloMonday Investor Webinar
6th Oct 20257:00 amRNSTrading Statement
24th Jul 20257:00 amRNSInterim Results
3rd Jul 20257:00 amRNSTrading Statement
7th Apr 20257:00 amRNSTrading Statement
31st Mar 20253:52 pmRNSDirector/PDMR Shareholding
31st Mar 20251:30 pmRNSResult of AGM
31st Mar 20257:00 amRNSAGM Trading Statement
3rd Mar 20257:00 amRNSFinal Results
13th Feb 202510:00 amRNSInvestor Presentation via Investor Meet Company
13th Jan 20257:00 amRNSTrading Statement
15th Oct 20247:00 amRNSTrading Statement
28th Aug 202410:58 amRNSDirector/PDMR Shareholding
29th Jul 20247:00 amRNSInterim Results
8th Jul 20247:00 amRNSTrading Statement
15th May 20246:24 pmRNSGranting of Options
27th Mar 20244:00 pmRNSResult of AGM
27th Mar 20247:00 amRNSAGM Trading Statement and Directorate Change
4th Mar 20247:00 amRNSFinal Results
19th Feb 20247:00 amRNSDirectorate Changes
24th Jan 20245:45 pmRNSHolding(s) in Company
23rd Jan 20245:00 pmRNSDirector/PDMR Shareholding - Replacement
23rd Jan 20241:09 pmRNSDirector/PDMR Shareholding
17th Jan 20243:51 pmRNSHolding(s) in Company
17th Jan 20241:45 pmRNSHolding(s) in Company
9th Jan 20247:00 amRNSTrading Statement
18th Dec 202311:45 amRNSHolding(s) in Company
11th Dec 20237:00 amRNSKonetik update
28th Nov 20237:00 amRNSDirectorate Changes
10th Nov 20234:01 pmRNSDirector/PDMR Shareholding
11th Oct 20237:00 amRNSBoard Changes - Replacement
10th Oct 20235:00 pmRNSBoard Changes
6th Oct 20237:00 amRNSTrading Update
26th Sep 20237:00 amRNSDirectorate Change
21st Sep 202311:00 amRNSDirector/PDMR Shareholding
15th Sep 20237:00 amRNSAcquisition of Konetik GmBH
3rd Aug 20233:50 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.